Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Middleton, G., Silcocks, P., Cox, T.F., Valle, J.W., Wadsley, J., Propper, D., Coxon, F.Y., Ross, P.J., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Robinson, A., McAdam, K., Eatock, M., &amp; EVANS, J. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <em>The Lancet Oncology</em>. https://doi.org/10.1016/s1470-2045(14)70236-0

Middleton G, Silcocks P, Cox TF, Valle JW, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology. 2014. doi:10.1016/s1470-2045(14)70236-0.

@article{gary2014Gemcit, title = {Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial}, author = {Gary Middleton and Paul Silcocks and Trevor F. Cox and Juan W. Valle and Jonathan Wadsley and David Propper and Fareeda Y. Coxon and Paul J. Ross and Srinivasan Madhusudan and Tom Roques and David Cunningham and Stephen Falk and Nick Wadd and Mark Harrison and Pippa Corrie and Timothy Iveson and Angus Robinson and Karen McAdam and Martin Eatock and JEFF EVANS and Caroline Archer and Tamas Hickish and Angel Garcia-Alonso and M. Nicolson and William P. Steward}, journal = {The Lancet Oncology}, year = {2014}, doi = {10.1016/s1470-2045(14)70236-0}, }